SCHEMBL9890754

SCHEMBL9890754

CNC(=O)Cc1ccccc1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.52
FFAR1 O14842 1/20 0.52
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
TRPV1 Q8NER1 3/20 0.44
SCN2A Q99250 1/20 0.44
SCN10A Q9Y5Y9 1/20 0.44
CSNK1D P48730 1/20 0.43
CHRM3 P20309 1/20 0.42
SCN9A Q15858 1/20 0.42
SLC6A4 P31645 1/20 0.42
LTA4H P09960 1/20 0.42
EPHX2 P34913 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP12 P39900 1/20 0.42
MMP3 P08254 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391528 0.86 PTGDR2 (0.51) CSNK1DMMP2MMP3
SCHEMBL2395131 0.82 KCNJ5 (0.49) FFAR4FFAR1MAPTRAB9ASLC6A4
SCHEMBL2395202 0.82 FFAR4 (0.55) FFAR4FFAR1MEN1KMT2AMAPT
SCHEMBL2391383 0.80 SLC6A4 (0.49) FFAR4FFAR1MEN1KMT2ARAB9A
SCHEMBL2397419 0.80 KMT2A (0.51) FFAR4FFAR1KMT2ARAB9ACHRM3
SCHEMBL2393550 0.77 SLC6A3 (0.48) FFAR4FFAR1MEN1KMT2AMAPT
SCHEMBL9890714 0.77 CYP2C19 (0.49) FFAR4FFAR1MEN1KMT2ACHRM3
SCHEMBL13329834 0.77 VNN1 (0.49) MEN1KMT2AMAPTCSNK1DEPHX2
SCHEMBL13329837 0.77 NLRP3 (0.57) MEN1KMT2AHTTLTA4HEPHX2
SCHEMBL2091466 0.74 FFAR4 (0.51) FFAR4FFAR1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 FFAR4 621/4885FFAR1 223/4885MEN1 1467/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 FFAR4 621/4885FFAR1 223/4885MEN1 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.